Zacks: Brokerages Set $2.67 Price Target for Antares Pharma Inc. (ATRS)
Antares Pharma Inc. (NASDAQ:ATRS) has received an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price objective of $2.67 for the company and are expecting that the company will post ($0.04) earnings per share for the current quarter, according to Zacks. Zacks has also given Antares Pharma an industry rank of 202 out of 265 based on the ratings given to its competitors.
Several research firms have recently weighed in on ATRS. Zacks Investment Research lowered shares of Antares Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, October 11th. Piper Jaffray Cos. restated an “overweight” rating and set a $2.00 price objective (down previously from $3.00) on shares of Antares Pharma in a research report on Saturday, August 13th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/zacks-brokerages-set-2-67-price-target-for-antares-pharma-inc-atrs.html
Several hedge funds and other institutional investors have recently made changes to their positions in ATRS. Janus Capital Management LLC purchased a new position in shares of Antares Pharma during the second quarter valued at approximately $102,000. Oppenheimer & Co. Inc. boosted its position in shares of Antares Pharma by 19.1% in the second quarter. Oppenheimer & Co. Inc. now owns 112,300 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 18,000 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Antares Pharma during the second quarter valued at approximately $133,000. LMR Partners LLP purchased a new position in shares of Antares Pharma during the second quarter valued at approximately $297,000. Finally, Royce & Associates LP boosted its position in shares of Antares Pharma by 318.3% in the first quarter. Royce & Associates LP now owns 406,900 shares of the specialty pharmaceutical company’s stock valued at $354,000 after buying an additional 309,616 shares during the last quarter. Institutional investors own 36.34% of the company’s stock.
Shares of Antares Pharma (NASDAQ:ATRS) traded down 0.893% during trading on Monday, reaching $1.665. 287,510 shares of the company traded hands. The firm’s market capitalization is $258.17 million. Antares Pharma has a 12 month low of $0.67 and a 12 month high of $1.85. The firm has a 50-day moving average price of $1.54 and a 200-day moving average price of $1.14.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). Antares Pharma had a negative net margin of 54.98% and a negative return on equity of 41.06%. The company earned $12.20 million during the quarter, compared to analyst estimates of $11 million. During the same quarter last year, the firm posted ($0.01) EPS. Equities research analysts anticipate that Antares Pharma will post ($0.15) EPS for the current year.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.